Check for updates

RESEARCH ARTICLE

REVISED Functional characterization of *Candida albicans* Hos2 histone deacetylase [version 2; peer review: 1 approved, 2 approved with reservations]

G Karthikeyan¹, Maneesh Paul-Satyaseela^{1,2}, Nachiappan Dhatchana Moorthy¹, Radha Gopalaswamy¹, Shridhar Narayanan^{1,3}

¹Drug Discovery Research, Orchid Chemicals and Pharmaceuticals Limited, Chennai, 600 119, India

²Current address: Samrud Foundation for Health & Research, Bangalore, 560106, India

³Current address: AstraZeneca India Pvt. Ltd, Bengaluru, 560024, India

V2 First published: 11 Nov 2013, 2:238
<https://doi.org/10.12688/f1000research.2-238.v1>
 Second version: 23 May 2014, 2:238
<https://doi.org/10.12688/f1000research.2-238.v2>
 Latest published: 22 Jul 2014, 2:238
<https://doi.org/10.12688/f1000research.2-238.v3>

Abstract

Candida albicans is a mucosal commensal organism capable of causing superficial (oral and vaginal thrush) infections in immune normal hosts, but is a major pathogen causing systemic and mucosal infections in immunocompromised individuals. Azoles have been very effective anti-fungal agents and the mainstay in treating opportunistic mold and yeast infections. Azole resistant strains have emerged compromising the utility of this class of drugs. It has been shown that azole resistance can be reversed by the co-administration of a histone deacetylase (HDAC) inhibitor, suggesting that resistance is mediated by epigenetic mechanisms possibly involving Hos2, a fungal deacetylase. We report here the cloning and functional characterization of *HOS2* (HighOsmolarity Sensitive), a gene coding for fungal histone deacetylase from *C. albicans*. Inhibition studies showed that Hos2 is susceptible to pan inhibitors such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), but is not inhibited by class I inhibitors such as MS-275. This *in vitro* enzymatic assay, which is amenable to high throughput could be used for screening potent fungal Hos2 inhibitors that could be a potential anti-fungal adjuvant. Purified Hos2 protein consistently deacetylated tubulins, rather than histones from TSA-treated cells. Hos2 has been reported to be a putative NAD⁺ dependent histone deacetylase, a feature of sirtuins. We assayed for sirtuin activation with resveratrol and purified Hos2 protein and did not find any sirtuin activity.

Keywords

C. albicans, HOS2, enzyme assay, histone/ tubulin deacetylase activity.

Open Peer Review

Approval Status

	1	2	3
version 3 (revision) 22 Jul 2014			
version 2 (revision) 23 May 2014	view		view
	↑		
version 1 11 Nov 2013	view	view	

1. **Donna MacCallum** , University of Aberdeen, Aberdeen, UK

2. **David Soll**, University of Iowa, Iowa City, IA, USA

3. **Malcolm Whiteway**, Concordia University, Montréal, QC, Canada

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: G Karthikeyan (karthik@orchidpharma.com)

Competing interests: No competing interests were disclosed.

Grant information: This was an exploratory in-house project funded solely by Orchid Chemicals and Pharmaceuticals Limited. *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

Copyright: © 2014 Karthikeyan G *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Karthikeyan G, Paul-Satyaseela M, Dhatchana Moorthy N *et al.* **Functional characterization of *Candida albicans* Hos2 histone deacetylase [version 2; peer review: 1 approved, 2 approved with reservations]** F1000Research 2014, 2:238 <https://doi.org/10.12688/f1000research.2-238.v2>

First published: 11 Nov 2013, 2:238 <https://doi.org/10.12688/f1000research.2-238.v1>

REVISED Amendments from Version 1

In this version of the manuscript, we have addressed the issues raised by both referees.

In the abstract and introduction section, we rephrased the first two lines to indicate that *C. albicans* can cause both superficial and systemic infection depending on the immune status of human hosts. In addition, we have included a missing word and rearranged a sentence in the abstract for clarity. The gene names mentioned in the introduction section are formatted in italics. In materials and methods section, we have given the total reaction volumes in micro litres to enzymatic assays involving purified Hos2 protein. In Figure 1B and Figure 5, the error bars are computed and the data sets are subjected to statistical tests (One way ANOVA) to determine the significance of difference between groups. The legend for the Y-axis in Figure 1B and Figure 5 has been changed to indicate the fold changes with respect to their respective controls/blank values. In Figure 2, the log concentration of HDAC inhibitor is corrected to micro molar in the dose response graph. We have modified the title of Figure 4 to correlate with the data presented on alpha tubulin. Finally, in the discussion section we have given our rationale in choosing tubulin as a substrate to Hos2 enzyme and discussed our findings in relevance to other published work.

See referee reports**Introduction**

Candida albicans is a commensal organism found in the mucosa and gastrointestinal tract of most healthy individuals but can cause superficial (oral and vaginal thrush) infections in immune-normal hosts and severe systemic infection in immunocompromised patients¹. This fungus is of clinical importance and is one of the leading causes of systemic infections in immunocompromised individuals. *C. albicans* is the fourth most common cause of nosocomial bloodstream infections and is associated with high mortality rates². Azoles and echinocandins targeting the ergosterol and cell wall biosynthesis pathway respectively have been used as anti-fungal drugs though the emergence of drug-resistant strains has compromised the efficacy and utility of these drugs³.

Azole resistance in *Candida* sp. is mediated by up regulation of genes encoding *ERG11*, a lanosterol demethylase⁴⁻⁶, *MDR1*^{5,7} and by *CDR* (Candida drug resistance) efflux pumps^{5,7-9}. A combination of existing anti-fungals with new classes of drugs that act by different mechanisms will be viable alternatives to the current monotherapy regimen, which contributes to the emergence of drug resistance.

Histone deacetylases (HDAC) play an important role in modulating chromatin conformation, by deacetylating crucial lysine residues in the histone octamers over which the chromatin DNA are wrapped¹⁰. Human HDAC's fall into four broad categories, Class I (HDAC1, 2, 3, and 8), Class II a (HDAC 4, 5, 7 and 9) Class II b (HDAC 6 and 10) Class III (sirtuins) and Class IV (HDAC11) based on sequence homology, substrate preference and co-factor requirements. The involvement of each of these isoforms in disease pathology has been elucidated to some extent in recent times. The approval of suberoylanilide hydroxamic acid (SAHA)¹¹, a well known inhibitor of HDACs by the US FDA for treating CTCL, (cutaneous T cell lymphoma)^{12,13} has thrown open the doors for exploring the use of

HDAC inhibitors in combination with existing drugs for several diseases, such as malaria and Kala-azar etc.,¹⁴⁻¹⁶.

Class specific inhibitors are now becoming a reality for human HDAC isoforms. For example the HDAC Class I specific inhibitor MS-275 is in advanced clinical trials (clinical trial Nos. NCT00020579, NCT00866333) for several forms of cancer, and the HDAC Class II specific inhibitor ACY-1215 is at an advanced clinical phase (clinical trial Nos. NCT01323751, NCT01583283) for myeloma.

HDAC inhibitors have been shown to synergize the actions of antifungal agents, due to their effect on preventing drug resistance *in vitro*^{17,18}. Therefore, an alternative approach to address fungal drug resistance could be to harness the potential of modulating fungal gene expression by inhibition of fungal HDACs^{17,19}.

Hos2, a Class I HDAC enzyme plays an important role in gene activation in the yeast *Saccharomyces cerevisiae* by binding to open reading frames (ORFs) of active genes²⁰. Hos2/Set3 histone deacetylase complex (Set3C) plays a key role in the conversion of white phase to virulent opaque phase in *C. albicans*²¹. Deletion of Hos2, the catalytic subunit of the Set3 complex produced a phenotype resembling inhibition of the Set3C by Trichostatin-A (TSA)²². Serum-induced morphogenesis of some *C. albicans* strains was shown to be inhibited by TSA¹⁹. Thus inhibiting the morphogenetic ability of this opportunistic pathogen using HDAC inhibitors holds the promise of future antifungal agents. Recently a small molecule, MGCD 290 (Hos2 inhibitor) has entered clinical trials (clinical trial number NCT01497223) for use in combination with azoles, such as fluconazole, for fungal infections¹⁸.

In light of the emerging utility of Hos2 inhibition as an anti-fungal strategy, we have cloned and characterized the *C. albicans* HOS2. In this report, we present details on optimizing the codons and cloning for heterologous gene expression in Sf9 insect cells. Purified Hos2 was characterized by functional deacetylase activities on histone/tubulin preparations and inhibition studies with SAHA, TSA and MS-275. The Candida genome database reports Hos2 to be a putative NAD⁺ dependent histone deacetylase²³, reminiscent of sirtuins. The Candida genome encodes for 3 sirtuins (HST1, HST2 and HST3). It has been shown that inhibition of HST3 by either gene repression or nicotinamide treatment reduces to a considerable extent the clinical severity of candidiasis²⁴. In light of this reported observation, we checked for sirtuin like activity of purified Hos2 preparations using resveratrol, which activates sirtuins²⁵.

Materials and methods**Isolation of *C. albicans* genomic DNA**

C. albicans ATCC 90028 was obtained from ATCC and grown in Sabouraud dextrose media. The protoplasts were prepared from an overnight culture of fully-grown mycelia using zymolyase (Cat. No. L5263, Sigma, St. Louis, MO, USA) as per the manufacturer's instructions. Protoplasts were lysed in a chaotropic salt solution and genomic DNA was isolated according to manufacturer's instruction (Qiagen, Hilden, Germany). The final eluate was reprecipitated with ammonium acetate and isopropanol and DNA quantified by UV spectrophotometer (Spectramax Gemini XS, Molecular devices, CA, USA).

Cloning and expression of HOS2 in an insect cell expression system

Oligos were designed with codon changes made for 4th and 271st serine residues. Full length *HOS2* gene was amplified by using 4 different primers (Table 1) using splicing by overlap extension (SOE PCR), so that codon usage could be maintained in any heterologous expression system. The full-length blunt end PCR product was cloned in to pJET1.2 cloning vector (CloneJET PCR Cloning Kit Thermo Scientific) and confirmed by restriction digestion using *Bam*HI and *Not*I. DNA sequencing using T7 promoter (forward, 5'-TAATAC GACTCACTATAGGG-3') and pJET1.2 (reverse, 5'-AAGAACATCGATTTTCCATGGCAG-3') sequencing primer ascertained the sequence of the recombinant Hos2 gene.

Recombinant baculoviruses were generated using the Bac-to-Bac® baculovirus expression system according to the instructions of the manufacturer (Cat. No. 10359-016, Invitrogen, Carlsbad, USA). Sf9 insect cells (Cat. No. B825-01, Invitrogen, Carlsbad, USA) were cultured in complete TMN-FH medium (Cat. No. 554760, BD Bioscience, NJ, USA) served as host cells for virus generation and/or protein production. The *HOS2* gene was cloned in frame with N-terminal hexa-histidine tag into the transfer vector pFastBac-HT B (Cat. No. 10584-027, Invitrogen, Carlsbad, USA) and transformed in to *Escherichia coli* DH10Bac cells (Cat. No. 10361-012, Invitrogen, Carlsbad, USA). Sf9 cells were transfected using cellfectin reagent (Cat. No. 10362-100, Invitrogen, Carlsbad, USA) with the recombinant bacmid, and the resulting viruses were tested for their ability to produce recombinant Hos2 protein using western blot. Production cultures were performed T-150 cell culture flasks (Greiner bio-one GmbH, Germany) at a density of 16×10⁶ cells per flask. The cultures were inoculated with recombinant baculovirus stocks at multiplicities of infection of 10. At 4 days after infection, cells were harvested by centrifugation at 1200 g for 15 min at 4°C in a tabletop centrifuge (Model 5804R, Eppendorf AG, Hamburg, Germany). Cell pellets were stored at -80°C until protein purification.

Purification of recombinant Hos2 protein

The infected Sf9 cell pellets were resuspended in in-house ice-cold lysis buffer [10 mM Tris pH 7.5, 130 mM NaCl, 1% triton X-100, 10 mM NaF, 10 mM NaPi (sodium phosphate), and 10 mM NaPPi (sodium pyrophosphate)] with 1 X EDTA free protease inhibitor cocktail (Cat. No. 539134, Calbiochem, Merck-Millipore, San Diego, CA). Insoluble material was removed by centrifugation (Model 5804R, Eppendorf AG, Hamburg, Germany) at 16000 g, 4°C for 15 min. The cleared lysate was processed for nickel affinity

chromatography. Briefly, the cell supernatant was loaded onto a 3-ml nickel-nitrilotriacetic acid-agarose resin (Ni-NTA agarose, Cat. No. 30210, Qiagen, Hilden, Germany) packed column pre-equilibrated with equilibration buffer (25 mM Tris-Cl pH 8.0, 300 mM NaCl). The column was washed with wash buffer (25 mM Tris-Cl pH 8.0, 300 mM NaCl, 20 mM imidazole). His-tagged Hos2 protein was eluted with buffer containing 300 mM imidazole (Sigma, St. Louis, MO, USA). The Hos2 protein preparation was dialyzed into buffer (25 mM Tris, pH 8.0, 138 mM NaCl, 10% glycerol) and kept in 100 µl aliquots at -70°C. The concentration of Hos2 protein in the final eluate was estimated by Bradford assay (Bio-Rad Laboratories, CA, USA).

Hos2 deacetylase enzymatic assay

HDAC inhibitors, namely SAHA, TSA or MS-275 were dissolved in DMSO as 10 mM stock and subsequently diluted in 1X assay buffer (50 mM Tris Cl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 2.5 mM MgCl₂, 1 mg/ml BSA). Enzymatic assay was carried out in triplicates using the fluorogenic Class I HDAC substrate, Boc-Lys (Ac)-AMC (Cat. No. I1875, Bachem AG, Bubendorf, Switzerland). Briefly, 0.5 µg of purified recombinant protein in a volume of 10 µl of assay buffer was incubated with 50 µl of appropriate concentration of HDAC inhibitors and 20 µM of substrate at 37°C for 1 hr in 100 µl reaction volume. Reactions were terminated by the addition of trichostatin A (TSA)/suberoylanilide hydroxamic acid (SAHA), trypsin (1 mg/mL) (Sigma, St. Louis, MO, USA) and left at 37°C for 15 min, before reading the plates in a fluorimeter (Spectramax Gemini XS, Molecular devices, CA, USA) at wavelengths 360 nm (ext) and 460 nm (emi).

Production of polyclonal anti sera against Hos2 protein

Female BALB/c mice were purchased from The Jackson Laboratory (Bar Harbor, ME) at 4 weeks of age and then housed at the animal facility, Orchid Chemicals and Pharmaceuticals for 2 weeks in a specific-pathogen free facility with a 12 h light cycle (6 am–6 pm) and a 12 h dark cycle (6 pm–6 am). Groups of four mice were housed in sterilised polypropylene cages covered with stainless steel grid top, lined with autoclaved clean rice husk bedding. All animal experimentations were approved by the institutional animal ethics committee (Protocol No. 01/IAEC-05/PPK/2009). The native Hos2 protein (expressed in pET-32 bacterial vector system and purified using nickel affinity chromatography under denaturing conditions) was emulsified in complete Freund's adjuvant and injected subcutaneously into two female BALB/c mice (20 µg/mice). Booster doses of the deacetylase antigen (20 µg/mice) were given

Table 1. Oligonucleotide primer pairs for the PCR amplification of Hos2 gene by SOE PCR.

Sl. No.	Primer Name	Primer sequence
1	PR1	5' AAAAGGATCCATGACGATATCCATAAGTGAAACAGATACG 3'
2	PR2	5' ATTATTAAATCCATTATGGAACCGTTAAT 3'
3	PR3	5' ATTAACGGTTCATAATGGATTAAATAAT 3'
4	PR4	5' CACCACTAGCGGCCGCTAAGTCATTAGTTCTCCTAGTTTGGTTTCA 3'

on the 14th and 21st day in Freund's incomplete adjuvant. Mice were bled 7 days after the second booster dose and polyclonal anti sera was separated after clotting the blood²⁶.

Cell culture

Jurkat, a human T lymphocyte cell line, and HeLa, a human cervical adenocarcinoma cell line was obtained from ATCC and were cultured in DMEM (Gibco, Life technologies) supplemented with 10% (v/v) fetal calf serum (FCS), 2 mM glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin (Gibco, Life technologies).

Isolation of nuclear histones from mammalian cells

Acetylated histones were isolated from HeLa cells treated with the HDAC inhibitor SAHA as per published protocol²⁷. The histone pellet was then resuspended in ultra pure water, stored in 50 µl aliquots at -70°C and the protein concentration was determined using a BCA kit (Pierce).

Isolation of histones from *Candida sp.*

C. albicans ATCC 90028 mycelia (~5 gm wet weight) were washed with water, centrifuged at 10,000 rpm for 10 minutes at 4°C and the mycelial pellet was resuspended in 50 ml of 0.1 mM Tris-HCl, pH 9.4, 10 mM DTT. The sample was incubated with shaking at 30°C for 15 min and pelleted. The pellet was washed with 50 ml of sorbitol/HEPES buffer (1.2 M sorbitol, 20 mM Hepes, pH 7.4) and left resuspended in the same buffer containing lyticase (1000 units) overnight at 30°C for spheroplasting²⁸. The sample was pelleted and proceeded to histone isolation using acid extraction as described previously²⁹. Acetone was added at 3:1 (vol/vol) to precipitate the histones, which were subsequently dissolved in 10 mM Tris, pH-8.0.

Deacetylation of nuclear histones

Acetylated histones isolated from SAHA treated HeLa cells were used for the deacetylation assay with recombinant Hos2 enzyme. In brief, purified acetylated histones (2 µg) were incubated with different amounts of recombinant Hos2 enzyme. Histone deacetylation with 300 ng of rhHDAC1 or rhHDAC6 (expressed in-house using Baculo-viral expression system) was used as a positive control. Deacetylation assays were carried out in 100 µl reaction volume for 1 hr at 37°C in reaction buffer (50 mM Tris Cl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 2.5 mM MgCl₂, 1 mg/ml BSA). At the end of incubation, the reaction was stopped by the addition of 1X Lammeli sample buffer. The protein samples were resolved by SDS-PAGE and immunoblotted with anti-acetylated H3 Histone (Ac-K-9) antibody to study the deacetylation of H3-histone by rHos2. The assay results are reproducible in three independent experiments.

Deacetylation of acetylated tubulin

Whole cell extracts from TSA (Sigma, St. Louis, MO, USA) treated Jurkat cells were used for the α -tubulin deacetylation assay with recombinant Hos2 enzyme. In brief, whole cell extract (10 µg) were incubated with 5 and 8 µg of recombinant Hos2 protein. Deacetylation assays were carried out in 100 µl reaction volume for 3 hr at 37°C in reaction buffer (50 mM Tris-Cl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 2.5 mM MgCl₂). At the end of incubation, the reaction was stopped by the addition of 1X Lammeli sample buffer. The protein

samples were resolved by SDS-PAGE and immunoblotted with either anti-acetylated α -tubulin or anti- α -tubulin antibodies. The assay results are reproducible in two independent experiments.

Western blotting

Recombinant Hos2 protein or the acetylated/deacetylated nuclear histones from deacetylation assays were separated on 10–15% SDS-polyacrylamide gels. The gels were stained with coomassie blue (Phast gel, Aersham) or electro-blotted onto nitrocellulose membrane (HyBond-C, Amersham), which was blocked with 5% nonfat dry milk (Cat No. 70166, Fluka, Sigma-Aldrich) in 0.1% Tween- 20 in TBS for 1 hr, followed by overnight incubation at 4°C with either the polyclonal mouse serum (dilution 1:4000 of the sera), rabbit polyclonal anti-acetylated H3-Histone (dilution 1:4000, Ac-K-9 of H3-Histone, Cat. No. 06-599; Millipore), mouse monoclonal anti-acetylated tubulin (dilution 1:15000, Cat. No. T7451, Sigma) or mouse monoclonal anti-tubulin antibody (dilution 1:150000, Cat. No. T6199, Sigma). After incubation with the appropriate horseradish peroxidase conjugated secondary antibodies (Bovine anti-mouse IgG HRP conjugate-dilution 1:7500, Santa Cruz, SC-2371, Goat anti-rabbit IgG-HRP Upstate (Millipore) 12-348, dilution 1:4000), supersignal west pico substrate (Thermo Scientific Pierce) was used for detection.

In vitro Sirt1 activation assay

HeLa nuclear extract (2 µg) or recombinant Hos2 enzyme (300 ng) was incubated with NAD⁺ (500 µM), Fluor de Lys®-Sirt1 (Enzo lifescience), varying concentrations of resveratrol (Cat. No. 0219605205, MP Biomedicals, Ohio, USA) (30, 100, 250 and 500 µM) in presence or absence of the pan-HDAC inhibitor trichostatin, in 50 µl reaction volume at 37°C for 30 min. The reaction was carried out in triplicate following manufacturer's protocol (Enzo lifescience).

Statistical analysis

All values are expressed as mean $\pm$ standard deviation and the graphs were generated using Graph-Pad Prism® (Version 4) for Windows (GraphPad Software, San Diego, California, USA. Statistical analysis was performed by one-way analysis of variance (ANOVA), followed by Bonferroni multiple comparison test for all parameters. Resultswere considered statistically significant at P < 0.05.

Results

HOS2 gene PCR

Codon usage in *C. albicans* is different from standard genetic code. The 4th serine and the 271st serine of *HOS2* are translated as leucine in both mammalian and in insect cell expression systems. Hence, these codons were mutated using oligonucleotide primers to express serine in the recombinant Hos2 protein. The PCR product was cloned in the pFastbac-HTB shuttle vector and subsequently into baculo viral DNA using the Bac-to-Bac expression system.

Protein expression and purification

The Hos2 enzyme was expressed in the baculoviral-insect cell expression system as a NH₂-terminal hexa histidine tagged fusion protein, which is detected on Western blot as a ~52 kDa protein using our own polyclonal anti-Hos2 anti-sera raised against Hos2

A **B**

Figure 1. Expression of his-tagged Hos2 in insect cells and its characterization. (A) Sf9 cells were infected with 10 MOI of recombinant Hos2 baculovirus for 72 hours and the soluble fraction was collected. Two μ g of protein was separated on a 10% SDS-PAGE. Lane 2 is coomassie stained SDS-PAGE and Lane 3 is Hos2 protein recognized by polyclonal anti sera from mice. Molecular weight markers are labeled at the left side (Lane 1) of the blot. (B) Concentration dependent increase in deacetylase activity following incubation of baculo expressed Hos2 with Boc-lys (ac)-AMC fluorogenic peptide substrate in 1 hr assay at 37°C. Assays were carried out in triplicates and analysed for statistical significance by one way ANOVA (Bonferroni's Multiple Comparison Test) using GraphPad Prism software.

protein in mice. SDS-PAGE analysis of purified protein revealed a major band at ~52 kDa (Figure 1A).

In vitro deacetylation assay using synthetic peptide substrate

Recombinant Hos2 enzyme was assayed for deacetylase activity using the synthetic deacetylase substrate, Boc-Lys (ac)-AMC. The total activity with Boc-Lys (ac) AMC showed the enzyme to be active in deacetylating the lysine residue and the activity increased significantly ($P < 0.05$) with an increase in Hos2 concentration (Figure 1B).

Tubulin deacetylation and rHos2 protein blots

2 Data Files

<http://dx.doi.org/10.6084/m9.figshare.841666>

The inhibition of deacetylation activity of recombinant Hos2 was studied using classical HDAC inhibitors namely SAHA, TSA and MS-275. TSA was very potent in inhibiting Hos2 with an IC₅₀ of 2.8 nM, SAHA inhibited Hos2 with an IC₅₀ of 65 nM (Figure 2, Table 2). However, MS-275 showed > 50% inhibition of Hos2 activity only at 10 µM (Table 3).

In vitro deacetylation assay using natural substrates

The ability of purified Hos2 protein to deacetylate acetylated histones was examined *in vitro* using acetylated nuclear histone preparation made from SAHA treated HeLa cells. The nuclear histones from HeLa cells were isolated using a modified protocol of Shechter *et al.*²⁷ and established the deacetylation assay using rhHDAC1/rhHDAC6 as controls along with rHos2. In these assays it was

Table 2. IC₅₀ values of standard HDAC inhibitors.

Sl. No.	Pan HDAC inhibitor	IC ₅₀ ± SE (nM)
1	SAHA	65.4 ± 2.4
2	TSA	2.8 ± 0.9

Table 3. Hos2 enzyme inhibition values of Class I HDAC inhibitor.

Sl. No.	Class I HDAC inhibitor	% inhibition ± SE	
		10 µM	1 µM
1	MS275	56.3 ± 0.9	46.3 ± 1.4

Inhibition profile of HDAC inhibitors with recombinant Hos2 enzyme

Figure 2. Dose-dependent inhibition of Hos2 deacetylase activity by SAHA (squares) and TSA (triangles). Recombinant Hos2 enzyme was incubated with different concentrations of pan-HDAC inhibitors (SAHA or TSA) and the enzyme activity assay was performed. Assays were carried out in triplicates and error bars were calculated using GraphPad prism software.

found that 0.3 µg of rhHDAC1 was able to deacetylate the nuclear acetylated histones as detected by an anti-H3-K9 histone antibody. Recombinant hHDAC1 was more potent in deacetylating lysine residues in H3-histones than rhHDAC6. However, no significant deacetylation of H3-Histone was seen with 0.3 µg of Hos2 (Figure 3A). Similar results were obtained with acetylated histones from *Candida* in the *in vitro* histone deacetylation assay with purified Hos2 protein (up to 3 µg, Figure 3B). In contrast, when recombinant Hos2 was incubated with mammalian acetylated α-tubulin, a significant reduction in acetylation of α-tubulin (K40) could be observed (Figure 4).

Deacetylase activities of rHos2 and dose response curves of rHos2 inhibition by standard HDAC inhibitors: UPDATE 1

5 Data Files

<http://dx.doi.org/10.6084/m9.figshare.1031581>

In vitro Sirt1 deacetylation assay using fluor-de-lys substrate

Since Hos2 is a putative NAD⁺ dependent deacetylase, a feature of sirtuin class of deacetylases, it was of interest to check if the Hos2 protein displayed any sirtuin like activity. The sirtuin-like activity in response to the sirtuin activator resveratrol was studied using fluor-de-lys, a synthetic Sirt1 substrate. HeLa nuclear extract was

Figure 3. Deacetylation assays of deacetylases with nuclear histones. **A.** Histone H3 acetylation determined by Western blot of extracted acetylated histones (2 µg) Control (Lane 1), incubated with 300 ng of recombinant Hos2 protein (Lane 2), recombinant human HDAC1 (HD1 Lane 3) and recombinant human HDAC6 (HD6 Lane 4) for 1 hour at 37°C in HDAC assay buffer. **B.** Histone H3 acetylation determined by Western blot of extracted acetylated histones (2 µg) isolated from *C. albicans*, incubated with different concentrations of recombinant Hos2 protein for 1 hour at 37°C in HDAC assay buffer.

Figure 4. Deacetylation assays of rHos2 with α tubulin. α-tubulin acetylation determined by Western blot of SAHA-treated whole cell extracts containing acetylated α-tubulin (10 μg) incubated with 0, 5 or 8 μg of recombinant Hos2 for 3 hrs at 37°C in HDAC assay buffer.

used as a positive control for sirtuin activity. In the presence of TSA where the HDAC activities are inhibited no appreciable NAD⁺ dependent deacetylase-like activity was seen, following incubation of Hos2 with different concentrations of resveratrol (Figure 5).

Sirtuin assay of purified Hos2 preparations using resveratrol: UPDATE 1

3 Data Files

<http://dx.doi.org/10.6084/m9.figshare.1031579>

Discussion

Pathogenic fungi are increasingly responsible for life threatening infections in the elderly and immunocompromised patients. While some species have intrinsic resistance to anti-fungals, others develop resistance during the course of treatment. Increasing anti-fungal resistance and treatment failures in patients is becoming a challenge.

The *Candida* genome encodes at least 3 distinct classes of histone deacetylases in addition to sirtuins. There are 8 different histone deacetylases (*HOS1*, *HOS2*, *HOS3*, *HDA1*, *HDA2*, *HDA3*, *RPD3*, *RPD31*) which all have distinct roles in the morphogenesis of *C. albicans*. HDAC inhibitors, by virtue of their ability to prevent antifungal resistance *in vitro*, have been proposed as antifungal adjuvants. Hos2 is a histone deacetylase and interacts with several proteins both in the cytoplasmic milieu as well in the nucleus³⁰. Hos2 along with Set3 (SET domain-containing protein 3) an associated protein, plays an important role in controlling gene expression by associating with transcriptionally active regions of the chromatin³¹.

It has been surmised that inhibiting Hda1 for example might enhance the anti-fungal effect of HDAC inhibitors by limiting hyphal development, while inhibiting Hos2 might contribute to limiting yeast development³². Hos2 has an essential function in morphogenesis especially during conditions of nitrogen starvation³³. The critical role of HDAC's in *C. albicans* pathogenesis and survival to anti-fungal treatment underscores the necessity to study HDAC function in this organism.

Figure 5. SIRT1 activation following incubation of Resveratrol with rHos2. Fold activation of the Sirt1 like activity following incubation of recombinant *Hos2* enzyme with different concentration of resveratrol in presence and absence of HDAC inhibitor trichostatin. Assays were carried out in triplicates and analysed for statistical significance by one way ANOVA (Bonferroni's Multiple Comparison Test) using GraphPad Prism software.

The increasing clinical incidences of azole resistant fungal infections in critical care patients, makes a good reason to find additional drug targets to control such diseases. There is at least one small molecule (MGCD 290) that inhibits Hos2 histone deacetylase that has progressed to clinical trials. MGCD 290 in combination with azoles was shown to be active against azole resistant yeasts and moulds¹⁸.

In order to better understand the role played by the *Candida* Hos2 enzyme we attempted to clone, express and characterize the protein in detail. This study describes the cloning, expression, purification and characterization of the Hos2 deacetylase enzyme from *C. albicans*.

We cloned and expressed the *HOS2* gene in baculoviral expression system as a 6x his-tagged protein, which exhibits classical deacetylase activity with the synthetic Boc-Lys (ac)-AMC peptide substrate. In our study, the yield of the Hos2 protein was generally low and probably could be attributed to difference in codon usage between *Candida* and Sf9 insect cells. This *in vitro* enzymatic assay, amenable to high throughput, could be used for screening potent fungal Hos2 inhibitors that could be a potential anti-fungal adjuvant.

Our studies with the recombinant Hos2 protein showed that it is susceptible to inhibition by standard HDAC inhibitors such as SAHA and TSA. We characterized the inhibition profile of purified proteins with SAHA and TSA and showed that TSA is a more potent inhibitor of Hos2 with an IC_{50} of 2.8 ± 0.9 nM compared to SAHA (IC_{50} 65.4 ± 2.4 nM). Our studies with the Class I HDAC inhibitor MS-275 showed that this inhibitor did not inhibit Hos2 deacetylase as effectively as the pan HDAC inhibitors SAHA or TSA, suggesting that *Candida* Hos2 is more similar to Class II deacetylases.

The recombinant Hos2 failed to deacetylate either mammalian or fungal nuclear histones, suggesting that the histones are not the preferred substrates for the Hos2 enzyme. The fact that, the recombinant Hos2 enzyme did not show any inhibition with the Class I inhibitor MS-275 led us to explore alternate substrates including tubulins, which are substrates for Class II histone deacetylases. Experiments with total lysates from Jurkat cells containing acetylated α -tubulin showed a dose dependent deacetylation albeit at higher concentration of Hos2 (> 5 μ g). Hos2 in essence resembles the Class II mammalian HDACs, specifically HDAC6 in its preference for tubulin deacetylation. It has been shown that microtubules in the fungal hyphae drive nuclear dynamics and cell cycle progression to morphogenesis³⁴. In view of the fact that Hos2 seems to preferentially deacetylate tubulins, it would be interesting to see if Hos2 inhibitors would act as anti-fungals, either as a monotherapy or in synergy, with existing anti-tubulin agents such as benomyl, nocodazole etc. The physiological relevance of tubulin deacetylation by Hos2 warrants further study.

The *Candida* genome database²³ predicts Hos2 protein to be a NAD⁺ dependent deacetylase. Sirtuins which are classified as Class III

deacetylases are NAD⁺ dependent enzymes activated by polyphenols such as resveratrol. Sirtuins have been proposed to regulate cellular metabolism, ageing and other related processes, specifically cellular stress response to caloric restriction, mediating life span extension. The role of resveratrol as a sirtuin activator has been resolved recently and it is now known that in addition to activating Sirt1, it also activates Sirt5, while inhibiting Sirt3²⁵. Thus inhibiting any sirtuin like activity with small molecule inhibitors could be another way of enhancing the activity of currently used anti-fungals. We evaluated the possibility of Hos2 being a sirtuin like enzyme with a known Sirt1 activator resveratrol. We did not observe any significant (*P* value 0.5317 and 0.4411, in the presence and absence of trichostatin respectively) activation of NAD⁺ dependent deacetylase activity with the fluor-de-lys substrate.

In conclusion this study establishes a functional assay for purified Hos2 protein. This *in vitro* enzymatic assay can be used to screen small molecule inhibitors of Hos2, which can synergise current anti-fungals in the clinic.

Data availability

figshare: Tubulin deacetylation and rHos2 protein blots, doi: [10.6084/m9.figshare.841666](https://doi.org/10.6084/m9.figshare.841666)³⁵

figshare: Sirtuin assay of purified Hos2 preparations using resveratrol: UPDATE 1, doi: [10.6084/m9.figshare.1031579](https://doi.org/10.6084/m9.figshare.1031579)³⁶

figshare: Deacetylase activities of rHos2 and dose response curves of rHos2 inhibition by standard HDAC inhibitors: UPDATE 1, doi: [10.6084/m9.figshare.1031581](https://doi.org/10.6084/m9.figshare.1031581)³⁷

Author contributions

GK, MPS and SN conceived the study. GK, NDM and RG designed the experiments. GK, NDM and RG carried out the research. GK and NDM prepared the first draft of the manuscript. All authors were involved in the revision of the draft manuscript and have agreed to the final content.

Competing interests

No competing interests were disclosed.

Grant information

This was an exploratory in-house project funded solely by Orchid Chemicals and Pharmaceuticals Limited.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements

The authors thank Dr. B. Gopalan, Chief Scientific Officer (CSO) for the encouragement and support and the Management of Orchid Chemicals and Pharmaceuticals Limited (www.orchidpharma.com), Chennai, India, for encouraging publication of this research.

References

1. Odds FC: **Candida and candidosis: a review and bibliography**: Bailliere Tindall; 1988.
[Reference Source](#)
2. Pfaller MA, Diekema DJ, Jones RN, *et al.*: **International surveillance of bloodstream infections due to Candida species: frequency of occurrence and *In vitro* susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program**. *J Clin Microbiol.* 2001; **39**(9): 3254–3259.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Fera MT, La Camera E, De Sarro A: **New triazoles and echinocandins: mode of action, *In vitro* activity and mechanisms of resistance**. *Expert Rev Anti Infect Ther.* 2009; **7**(8): 981–998.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Sanglard D, Ischer F, Koymans L, *et al.*: **Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents**. *Antimicrob Agents Chemother.* 1998; **42**(2): 241–253.
[PubMed Abstract](#) | [Free Full Text](#)
5. White TC: **The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans**. *Antimicrob Agents Chemother.* 1997; **41**(7): 1488–1494.
[PubMed Abstract](#) | [Free Full Text](#)
6. Song JL, Harry JB, Eastman RT, *et al.*: **The Candida albicans lanosterol 14-alpha-demethylase (ERG11) gene promoter is maximally induced after prolonged growth with antifungal drugs**. *Antimicrob Agents Chemother.* 2004; **48**(4): 1136–1144.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Sanglard D, Kuchler K, Ischer F, *et al.*: **Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters**. *Antimicrob Agents Chemother.* 1995; **39**(11): 2378–2386.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Albertson GD, Niimi M, Cannon RD, *et al.*: **Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance**. *Antimicrob Agents Chemother.* 1996; **40**(12): 2835–2841.
[PubMed Abstract](#) | [Free Full Text](#)
9. Marr KA, Lyons CN, Rustad TR, *et al.*: **Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR**. *Antimicrob Agents Chemother.* 1998; **42**(10): 2584–2589.
[PubMed Abstract](#) | [Free Full Text](#)
10. Clayton AL, Hazzalin CA, Mahadevan LC: **Enhanced histone acetylation and transcription: a dynamic perspective**. *Mol Cell.* 2006; **23**(3): 289–296.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Marks PA: **Discovery and development of SAHA as an anticancer agent**. *Oncogene.* 2007; **26**(9): 1351–1356.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Campas-Moya C: **Romidepsin for the treatment of cutaneous T-cell lymphoma**. *Drugs Today (Barc.)*. 2009; **45**(11): 787–795.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Duvic M, Vu J: **Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat**. *Biologics.* 2007; **1**(4): 377–392.
[PubMed Abstract](#) | [Free Full Text](#)
14. Dokmanovic M, Clarke C, Marks PA: **Histone deacetylase inhibitors: overview and perspectives**. *Mol Cancer Res.* 2007; **5**(10): 981–989.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Mai A: **The therapeutic uses of chromatin-modifying agents**. *Expert Opin Ther Targets.* 2007; **11**(6): 835–851.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Riestler D, Hildmann C, Schwienhorst A: **Histone deacetylase inhibitors—turning epigenetic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases**. *Appl Microbiol Biotechnol.* 2007; **75**(3): 499–514.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Smith WL, Edlind TD: **Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation**. *Antimicrob Agents Chemother.* 2002; **46**(11): 3532–3539.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Pfaller MA, Messer SA, Georgopapadakou N, *et al.*: **Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens**. *J Clin Microbiol.* 2009; **47**(12): 3797–3804.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Simonetti G, Passariello C, Rotili D, *et al.*: **Histone deacetylase inhibitors may reduce pathogenicity and virulence in Candida albicans**. *FEMS Yeast Res.* 2007; **7**(8): 1371–1380.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Wang A, Kurdistan SK, Grunstein M: **Requirement of Hos2 histone deacetylase for gene activity in yeast**. *Science.* 2002; **298**(5597): 1412–1414.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Hnisz D, Schwarzmuller T, Kuchler K: **Transcriptional loops meet chromatin: a dual-layer network controls white-opaque switching in Candida albicans**. *Mol Microbiol.* 2009; **74**(1): 1–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Hnisz D, Majer O, Frohner IE, *et al.*: **The Set3/Hos2 histone deacetylase complex attenuates cAMP/PKA signaling to regulate morphogenesis and virulence of Candida albicans**. *PLoS Pathog.* 2010; **6**(5): e1000889.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Inglis DO, Arnaud MB, Binkley J, *et al.*: **Candida Genome Database**.
[Reference Source](#)
24. Wurtele H, Tsao S, Lepine G, *et al.*: **Modulation of histone H3 lysine 56 acetylation as an antifungal therapeutic strategy**. *Nat Med.* 2010; **16**(7): 774–780.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Gertz M, Nguyen GT, Fischer F, *et al.*: **A molecular mechanism for direct sirtuin activation by resveratrol**. *PLoS One.* 2012; **7**(11): e49761.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Fuller SA, Takahashi M, Hurrell JG: **Immunization of Mice**. *Curr Protoc Mol Biol.* John Wiley & Sons, Inc.; 2001.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Shechter D, Dormann HL, Allis CD, *et al.*: **Extraction, purification and analysis of histones**. *Nat Protoc.* 2007; **2**(6): 1445–1457.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. **Yeast Nuclei Isolation**.
[Reference Source](#)
29. Knapp AR, Ren C, Su X, *et al.*: **Quantitative profiling of histone post-translational modifications by stable isotope labeling**. *Methods.* 2007; **41**(3): 312–319.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Wiren M, Silverstein RA, Sinha I, *et al.*: **Genomewide analysis of nucleosome density histone acetylation and HDAC function in fission yeast**. *EMBO J.* 2005; **24**(16): 2906–2918.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Hnisz D, Bardet AF, Nobile CJ, *et al.*: **A histone deacetylase adjusts transcription kinetics at coding sequences during Candida albicans morphogenesis**. *PLoS Genet.* 2012; **8**(12): e1003118.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Zacchi LF, Schulz WL, Davis DA: **HOS2 and HDA1 encode histone deacetylases with opposing roles in Candida albicans morphogenesis**. *PLoS One.* 2010; **5**(8): e12171.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Robyr D, Suka Y, Xenarios I, *et al.*: **Microarray deacetylation maps determine genome-wide functions for yeast histone deacetylases**. *Cell.* 2002; **109**(4): 437–446.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Finley KR, Berman J: **Microtubules in Candida albicans Hyphae Drive Nuclear Dynamics and Connect Cell Cycle Progression to Morphogenesis**. *Eukaryot Cell.* 2005; **4**(10): 1697–1711.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Karthikeyan G, Maneesh PS, Nachiappan DM, *et al.*: **Tubulin deacetylation and rHos2 protein blots**. *figshare.* 2014.
[Data Source](#)
36. Karthikeyan G, Maneesh PS, Nachiappan DM, *et al.*: **Deacetylase activities of rHos2 and dose response curves of rHos2 inhibition by standard HDAC inhibitors**. *figshare.* 2014.
[Data Source](#)
37. Karthikeyan G, Maneesh PS, Nachiappan DM, *et al.*: **Sirtuin assay of purified Hos2 preparations using resveratrol**. *figshare.* 2014.
[Data Source](#)

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 26 June 2014

<https://doi.org/10.5256/f1000research.4538.r5126>

© 2014 Whiteway M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Malcolm Whiteway

Department of Biology, Concordia University, Montréal, QC, Canada

- Figure 1a protein purification is OK, and the the signal with the antibody to the purified protein is fine, but needs the control lane with extract from uninfected cells.
- The presentation of the activity in Figure 1b is a bit unorthodox. Why not just present the blank and the experiment for each concentration, and if you want to present the fold activity with respect to blank, it can be a figure below the blank and experimental bars.
- Deacetylation assays support activity only with alpha tubulin, not histones.
- For the sirtuin assay, a positive control would be informative; can you see activation of a pure sirtuin in the assay performed.

Minor Comments - in the first line of the Results, it would be better to say the first CUG and 271st CUG codon rather than serine.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 07 Jul 2014

Karthikeyan Ganesan, Orchid Chemicals and Pharmaceuticals Limited, Chennai, India

The points raised by the referee are addressed in the new version of the article. We have carried out a separate experiment to show that the signal in the western blot is specific (this can be downloaded [here](#) but is not included in the revised article).

Fig 1B was specifically modified at the request of the editorial team during the initial stage and subsequently modified based on inputs from other referee(s).

The title has now been modified to reflect that tubulins are deacetylated and not histones.

We used HeLa nuclear extracts as positive control for Sirtuin assay and Resveratrol did show Sirtuin activation.

Minor Comment regarding the mention of 1st and 271st CUG codon will be modified in the revised article.

Competing Interests: No competing interest

Reviewer Report 11 June 2014

<https://doi.org/10.5256/f1000research.4538.r4908>

© 2014 MacCallum D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Donna MacCallum

Aberdeen Fungal Group, University of Aberdeen, Aberdeen, UK

Authors have addressed prior concerns.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 16 April 2014

<https://doi.org/10.5256/f1000research.2168.r4017>

© 2014 Soll D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

David Soll

Department of Biology, University of Iowa, Iowa City, IA, USA

This manuscript describes an *in vitro* assay strategy for testing the effects of antifungal compounds on the activity of Hos2 deacetylase large scale screens. The goal is to find compounds that could be used as facilitators in combinatorial drug treatments for azole resistant *Candida albicans* infections. Although *in vitro* assays are sometimes useful for developing *in vivo* strategies, they are not ideal for screening and identifying optimal drugs.

As shown in this study by the authors, the recombinant Hos2 they generated exhibits paradoxically tubulin-specific deacetylase activity and not Hos2 specific activity. This finding seems to undermine their intent, because anti-tubulin deacetylase activity or anti-human HDAC6 activity demonstrated *in vitro* could be an artifact of the recombinant protein. In addition, anti-tubulin and anti-HDAC6 activity might result in adverse side effects on human host functions and thus affect the specificity of the primary drug.

It is surprising that the recombinant Hos2 did not show any activity in acetylating either the human or *Candida* histone H3 *in vitro*, despite the fact that several earlier studies in *C. albicans* has demonstrated that Hos2 is involved in morphogenetic programs by affecting chromatin function. In addition, an isolated study has demonstrated the efficacy of a Hos2-specific inhibitor on azole-resistant strains of *C. albicans* (Pfaller *et al.*, 2009), which is quoted by the authors. The authors do state in the introduction that Hos2 is not a typical deacetylase and has been described by the *Candida* Genome Database as a member of NAD-dependent sirtuins. The authors' data show that their recombinant version lacks this activity, but does exhibit inhibition by classical inhibitors of histone deacetylases.

In addition to this major problem there are a few other aspects of the paper that need to be addressed:

- Firstly, Figure 1 and Figure 5 do not have error bars to indicate reproducibility of the data. Also, a statistical analysis of data sets would be useful to indicate the significance of the results.
- Secondly, the units in Figure 2 and Table 2 need to be consistent with the units described in the text.
- Thirdly, since Figure 4 shows the effect of recombinant Hos2 on only tubulin, the title needs to be changed to indicate that the assay was not done with purified histones.
- Finally, it is not clear what "fold activity" (in Figure 1B) and "fold activation" (Figure 5) refer to.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 13 May 2014

Karthikeyan Ganesan, Orchid Chemicals and Pharmaceuticals Limited, Chennai, India

As a pharmaceutical organization, involved in drug discovery, our initial compound libraries are screened for *in vitro* activity/inhibition assays. These *in vitro* assays act as important filters removing in-active compounds to progress only the most potent ones to *in vivo* screening.

Deacetylase assays using recombinant Hos2 enzyme and synthetic substrate Boc (Lys) AMC showed that the enzyme is active in standard fluorogenic assays. Absence of deacetylase activity with histone preparations (Human/*Candida*) in the *in vitro* histone deacetylation assays was a surprise but the fact that Class I HDAC inhibitor like MS-275 did not inhibit rHos2 in standard fluorogenic assays, led us to explore alternate substrate, namely tubulins.

We do agree with the reviewer that anti-tubulin deacetylase activity could be an artifact of recombinant protein, but we strongly feel that it is a remote possibility.

Any small molecule that shows anti-tubulin or anti-HDAC6 activity would be picked up in the *in vitro* screen and would be prevented from moving further up the discovery path. (Which can be re-purposed for different therapeutic)

We are indeed aware of the previous studies showing the effect of Set3/Hos2 complex and the opposing roles of Hda1 and Hos2 in *Candida* morphogenesis as well as the role of Hos2 in *S. cerevisiae*. In these studies Histone H4 acetylation levels vary dramatically, especially H4-K16, however the Histone H3 levels more or less remain constant, (supplementary materials from Wang *et al.*, 2002) and that's probably the reason why we don't see any dramatic deacetylation when probed with Histone H3-K9. The study by Pfaller *et al.* did have *in vivo* data, but did not have any *in vitro* data.

Error bars and statistical analysis have been incorporated for Figs. 1 and 5. Units for Fig. 2 and Table 2 corrected.

Label has been changed for Fig. 4

Fold activity and Fold activation is with respect to Blank and has been reflected in the figures.

Competing Interests: No competing interests were disclosed.

Reviewer Report 19 March 2014

<https://doi.org/10.5256/f1000research.2168.r4016>

© 2014 MacCallum D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Donna MacCallum

Aberdeen Fungal Group, University of Aberdeen, Aberdeen, UK

This is an interesting study designed to examine the biological activities of *Candida albicans* Hos2 enzyme, a putative histone deacetylase. The authors express a recombinant version of the protein, which has a His tag added to the N-terminus, and use this to explore potential substrates for the enzyme.

There are a number of major issues with the data as presented, which need to be addressed:

- It is difficult to make any conclusions from the quantitative data presented in the figures as there are no error bars and the number of replicates is not stated. In addition, it is unclear what the data in Figures 1B and 5 has been expressed relative to (i.e. fold change relative to...?) Statistical analyses should also be carried out to determine whether any differences are statistically significant ones.
- The authors should also revisit the data presented in Figure 2 and Table 2. The data does not correlate, as the authors suggest that the IC₅₀ values are in micromolar amounts, yet the data in the figure would suggest millimolar levels - units should be checked.
- The title for Figure 4 should be modified, since this figure contains only data for beta-tubulin.
- In the main text the authors need to be much clearer regarding the rationale for looking at tubulin as a substrate. The authors may also wish to consider the possibility that the substrate specificity and/or activity may have been affected by the N-terminal tag and how this could be investigated.
- The discussion section should be revisited to remove the reiteration of the introduction and results. Instead, use this part of the paper to discuss the findings in relation to other published work.

Minor points:

- *Candida albicans* is capable of causing superficial (oral and vaginal thrush) infections in immune normal hosts (abstract and introduction).
- Gene names, e.g. *CDR1* and *ERG11*, should be in italics.
- For the enzymatic assay it would be good to state the volume of the assay so that final concentrations can be worked out.
- Figure and table legends should include the number of replicates carried out to generate the data.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 13 May 2014

Karthikeyan Ganesan, Orchid Chemicals and Pharmaceuticals Limited, Chennai, India

Error bars have been incorporated and where possible, statistical analysis done and reported.

Error in reporting IC₅₀ value in Table 2 and Fig. 2 is corrected.

Title for Fig. 4 changed to reflect tubulin deacetylation.

The rationale for choosing tubulin as a substrate has been explained. We agree with the reviewer that N-terminal tag could perhaps play a role, although we consider that as a remote possibility.

Minor points suggested by reviewer has also been addressed.

Competing Interests: No competing interest

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research